Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient.
Shizuoka Cancer Center, Division of Thoracic Oncology, Shizuoka, Japan.
Hiromichi
H
Shirasu
Shizuoka Cancer Center, Division of Thoracic Oncology, Shizuoka, Japan. Electronic address: a.ono@scchr.jp.
Akira
A
Ono
Shizuoka Cancer Center, Division of Thoracic Oncology, Shizuoka, Japan.
Toshiaki
T
Takahashi
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D000077594:Nivolumab
D000911:Antibodies, Monoclonal; D000077594:Nivolumab